slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 77,311-77,340
Pages 3,679
Rows per page 30
Component
77,311-77,340 of 110,355
44
The chart uses a complex network of bidirectional arrows to define reporting, advisory, and support relationships.Evotec | Investor Presentation Deck | 49 slides · Evotec
Conference presentation Investor relations Beat · Action1 hit
48
The slide uses a donut chart to visualize the ownership distribution.Evotec | Investor Presentation Deck | 49 slides · Evotec
Conference presentation Investor relations Beat · Action1 hit
04
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · What Is1 hit
10
The slide uses a Gantt-style visualization for drug development stages.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Loop · Golden Circle1 hit
11
The slide uses a table structure to compare three partners (BMS, Merck KGaA, Sanofi) across four metrics: number of collaborations, cash inflows, milestones, and royalty tiers.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Loop · Golden Circle1 hit
12
Includes footnotes regarding tax withholding, cash composition, and share count.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Loop · Golden Circle1 hit
24
The scatter plot demonstrates the 'active learning' selection process vs standard coverage properties.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Aha Moment1 hit
25
The slide uses a horizontal layout to showcase four distinct technical pillars of the company's R&D infrastructure.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
39
The slide uses a circular process flow to represent a proprietary R&D pipeline.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
41
The slide uses Kaplan-Meier curves to demonstrate clinical efficacy of the platform's drug prioritization.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
42
The slide uses a converging timeline/process flow to show how different patient types (Ovarian cancer vs AML) feed into a unified precision medicine testing platform.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
43
Uses a complex heatmap/dot-plot visualization to show drug sensitivity across different samples and cell lines.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
44
The slide uses a small multiples approach to show individual patient responses, then aggregates them into two groups (I and II) to demonstrate differential sensitivity.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
50
Includes a biological pathway diagram and a list of potential cancer indications.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
53
Data source: Besnard et al, AACR (2022).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
57
Includes a Venn diagram and two line charts showing Log2FoldChange vs concentration.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
63
The slide uses a human anatomy diagram to map specific patient counts to disease locations.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
64
The slide uses a hub-and-spoke diagram to illustrate the interaction of LSD1 with various protein complexes, receptors, and RNAs.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
65
The slide uses a biological process diagram to explain the mechanism of action for a drug candidate ('539).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
66
The slide uses a process flow diagram to explain the therapeutic mechanism.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
70
The slide outlines a specific workflow involving generative design, ML, and active learning.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
72
The slide uses two distinct chart types (dot plot and line chart with error bars) to illustrate the safety profile of the drug candidate '539.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
73
Data shows heterogeneity of response across different patient samples, categorized by differentiation level.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
74
The slide uses a heatmap to visualize synergy (green = yes, light green = no) across 6 drug combinations and 14 patient samples.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
75
Includes statistical significance markers (asterisks) and safety observation regarding body weight.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
77
The heatmap displays AUC values for 16 patient samples across three treatments.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 1 hit
79
MIDD = Model-informed Drug DevelopmentExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 1 hit
88
The slide presents preclinical efficacy data for a MALT1 inhibitor ('565) in combination with Ibrutinib.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 1 hit
90
The table uses a heatmap-style color coding (red/green) to indicate risk levels.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 1 hit
04
The slide uses a Gantt-style visualization to represent drug development stages.Exscientia | Results Presentation Deck | 22 slides · Exscientia
Conference presentation Investor relations 1 hit